China Shenghuo Pharmaceutical Holdings Inc (fka CKUN)

[Renee]

CKUN: Company Going Private; 1-380,000 R/S whereby fractional shares will be cashed out at $0.16 per pre-split share.

http://www.otcbb.com/asp/dailylist_detail.asp?d=05/16/2013&mkt_ctg=NON-OTCBB

[dannie30]

The Special Committee of China Shenghuo Pharmaceutical Accepts Going Private Proposal From Lan's Int'l Medicine Investment Co., Limited at $0.16 per Share to Be Effected Through a Reverse Stock Split

http://finance.yahoo.com/news/special-committee-china-shenghuo-pharmaceutical-120000824.html

[dannie30]

Product >> http://www.shenghuo.com.cn/en/Product.aspx

[dannie30]

China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2012

http://www.shenghuo.com.cn/en/ShowNews.aspx?Big_Id=2&Small_Id=10&NewsID=77

[dannie30]

yeah its otcqb now

[tmonkey]

DELISTING---READ LAST REPORT-----tmonkey

[dgtams]

What happened here? Why the big drop? Maybe a bounce after it goes to .05 or less?

[tmonkey]

soon to join pinkie land------------had this awhile back and looked promising----dont know how they screwed it up...has really fallen off a cliff---just one of many ch cos killing investors----many either criminal or they just dont have a clue-------------------tmonkey

[Penny Roger$]

~ Monday! $KUN ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $KUN ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=KUN&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=KUN&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=KUN
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=KUN#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=KUN+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=KUN
Finviz: http://finviz.com/quote.ashx?t=KUN
~ BusyStock: http://busystock.com/i.php?s=KUN&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=KUN >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[joenatural]

Actually, I'm shorting today's KUN that's miles overvalued, but best of luck to you and congrats on your profits. Hope you saw the dramatic drop-off in volume late today, a sign that the stock will now head back to reality. The stock went 21 minutes without trading at all today .........

"Poor Joe is still shorting the KUN of two years ago >> $2+ on deck"

[wickerman]

Poor Joe is still shorting the KUN of two years ago >> $2+ on deck

[steeledge]

Looks like you'll have your chance

[joenatural]

Shorted a few more at $1.70 pre-market this morning, but didn't get carried away. I'll start getting carried away over $2.00

[steeledge]

Joe is a terrific trader, and for high-momentum stocks like KUN, there's always $ to be made both ways. The trick of course is not shorting too heavily too early. I wouldn't have wanted to be a SHZ short at 1.50, but the parallels between SHZ and KUN aren't numerous.

KUN will payoff in both directions, but it's a matter of timing.

[S3lfMade]

20m O/S~ 4m float..unreal potential with them revs and approvals in the waiting

[joenatural]

Well so far you're kicking my butt and yes, I realize what's now behind the company, but at the same time, I'm a fundamentalist that understands valuation to a tee. Nice momo now and I (even though I'm short at $1.40, but lightly) won't mind a further rise in the price, as I'll start adding a little heavier to short position ......

"Will do and thanks. On your end, try and keep in mind that the current KUN is not the company of years past which imo is the KUN that you are basing your bearish opinion on."

[wickerman]

Will do and thanks. On your end, try and keep in mind that the current KUN is not the company of years past which imo is the KUN that you are basing your bearish opinion on.

[joenatural]

I won't need luck in knowing this stock has reached P.O.S. status with regards to valuation. Whoever pumped this made some nice cash, but the party will end with the stock well below $1.00 and even then it's still expensive. Good luck.

[wickerman]

.04 eps//old lawsuit settlement//delisting issue removed//low float//hot sector//all hype themselves. Good luck on that.

[joenatural]

Went short at $1.40 on the very unwarranted run-up and hype. Geez people, read their latest SEC filings. Hoping further hype takes this on up, but if not, that's fine as well.

[wickerman]

$1.45 KUN over 100k volume

[$maker$]

[wickerman]

$1.17 KUN breakout chart >>> Chinese daytraders are going to pounce on the first solid close well over $1

KUN is the SHZ of 2011 and all the pieces are coming together.

[wickerman]

KUN $1.05 volume 45k

[steeledge]

$1 is 52wk high, and after that who knows how high it goes. Exciting.

[wickerman]

.99 KUN will be a monster once it breaks through and closes above $1 >> same ultrabullish early setup as SHZ and most traders are still asleep on it like they were on SHZ at $1

ROE of over 92% which will be getting even better.

[steeledge]

Some decent volume today too

[wickerman]

KUN .93 offer getting chewed

[wickerman]

KUN chart >> once the .95 April 14 volume high gets taken out on over 100K volume this stock is going to break out in a major way imo. Wasn't ready today as it gapped up to exactly .95 and then got taken down and backfilled, but it is surely coming..

Been adding KUN in the .80's all day, and yvw for the monstrous 2010 SHZ ten-bagger...hopefully KUN will do the same in 2011. Have a great New Year as well!

[ventrikel]

..i did the same- followed you on SHZ-Postings.
Its time to thank you for "SHZ", mabe the time for KUN is soon coming.

Have a great day and a good new year!!!

[wickerman]

KUN three month chart ~~ res @ .82 .90 .96

Biopharma not a sexy sector like SHZ so not much love for the moment. In time that will change as sub-dollar stocks with growing .04 EPS are hard to ignore for too long.

I've been accumulating this stock a few k every day. Lawsuit settlement, delisting danger gone, not much holding it back anymore except low volume.

[ventrikel]

Why is this stock so undervalued?

[steeledge]

It's just a matter of time. One by one the sub-$1 biotechs are getting nice runs. None of those have earnings, many are listing deficient. Technically KUN still is but they at least have an accepted compliance plan from Amex. Regardless, this one is thin, profitable, and I am happy to own it from the low .50's

[wickerman]

.82 KUN small cap bio with .04 EPS and a breakout chart

[wickerman]

KUN chart is eerily similiar to FFHL/SHZ

[wickerman]

KUN .78 major break over .73 resistance level on heavy volume

[wickerman]

KUN chart >> another SHZ-type multibagger in the making which no one cares about under $1 but will love at $4

.04 EPS and delisting danger removed >>> breakout coming over .73

[wickerman]

KUN massive breakout @ .73 >> the delisting danger was the only thing holding it back and now that is gone. EPS of .04 with ROE over 94%.

http://www.prnewswire.com/news-releases/nyse-amex-accepts-china-shenghuos-compliance-plan-for-continued-listing-111509314.html

[deadjim]

nice chart and nobody here... lol

[RagingStocks]

China Shenghuo Announces Management Expansion and Enhanced Internal Controls

KUNMING, China, March 4, 2009 /PRNewswire-Asia-FirstCall via COMTEX/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" or the "Company"), today announced the expansion of its senior management team to better align with the Company's business outlook, to optimize operations, and increase efficiencies across the organization. The Company expanded the number of senior management personnel from 5 to 9 in preparation for the anticipated growth in its sales and operations. Additional measures were implemented to support, monitor and further enhance existing internal controls to strengthen the Company's reporting and governance.
Furthermore, the Company recently appointed two new independent directors to the Company's Board of Directors. Both new directors are experts in their respective industry, namely, accounting and corporate finance, and research and development in traditional Chinese medicine.

"An optimally structured senior management is vital as we recognize how significant the next stage of development is for the Company. We have installed senior level executives with specific areas of expertise to make us a more effective company," commented Mr. Gui Hua Lan, Chairman of China Shenghuo. "It is also very important that we continue to strengthen our Board with seasoned professionals experienced in drug development, the capital markets, and corporate governance. The expanded management team will lead the Company to become more efficient, and reinforces the Company's commitment to new drug development to attain the growth and performance targets we have set."

Senior management recently implemented a series of measures designed to improve and strengthen its internal control framework. Of particular importance are enhanced internal controls for financial reporting. In addition, management made significant improvements in the transparency and efficiency within each department. Each department is required to submit a set of operational guidelines to senior management for approval and then strictly adhere to these rules. Recognizing that improving the knowledge base of the workforce strengthens the overall competitive position of the Company; training programs have been made available to all employees. Courses in sales, marketing and planning, research and development, production techniques, and leadership training are offered. The educational programs are designed to enhance employees' performance within their department and the Company culture.

"It is imperative for the Company to improve its internal control systems as it helps management obtain timely and accurate information to make both tactical and strategic decisions. Effective internal controls are one of the keys to accountability," continued Mr. Lan. "Our improvements are focused on making the new management structure more efficient so we achieve long-term sustainable growth."

"As we look ahead to the next four years, our expanded senior management team has a mandate to foster the growth of our operations. The goal is for management to achieve annual revenue and net income growth of 25% during this period. The improved internal control measures will help us manage this expected growth as well as minimizing our operating risk. We will leverage our strength in R&D, production and sales to become an industrial leader in our sector. We expect to finish the application for a new series of first-aid medicines for the treatment of trauma. Our plan is designed to provide a healthy drug pipeline to produce new drugs to the market," concluded Mr. Lan.

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; risks arising from potential weaknesses or deficiencies in the Company's internal controls over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



For more information, please contact:

China Shenghuo Pharmaceutical Holdings, Inc.
Mr. Changhua Mu
Securities Affairs Representative
Tel: [phone]
Email: [e-mail]

Grayling
Eddie Cheung
Investor Relations
Tel: [phone]
Email: [e-mail]

SOURCE China Shenghuo Pharmaceutical Holdings, Inc.


URL: http://www.shenghuo.com.cn
www.prnewswire.com

[tmonkey]

i followed this on the way down to 1.89 when they got into that mess---i always thought what they so is great especially if they could up their exports---with a new trading range of .34-.80 i am watching closer from here on---tmonkey

[The Night Stalker]

i advise you to stay away from KUN OR ELSE


volume sucks, charts say its reached its peak, nothing to see hear

[johnsdr]

Does anyone this this is a good buy right now?

[RagingStocks]

KUN Health Food:



http://www.shenghuo.com.cn/en/Product.aspx?BigId=3

[RagingStocks]

KUN Cosmetic Lines:



http://www.shenghuo.com.cn/en/Product.aspx?BigId=2

[RagingStocks]

KUN Drug lines:



http://www.shenghuo.com.cn/en/Product.aspx?BigId=1

[RagingStocks]

Most Recent news: China Shenghuo Announces Additional Roll-Out of '12 Ways' Cosmetics Products to Watsons Stores
Tuesday December 9, 2008, 8:30 am EST
Yahoo! Buzz Print Related:China Shenghuo Pharmaceutical Holdings, Inc.
KUNMING, China, Dec. 9 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" or the "Company"), today announced that the Company is expanding its herbal-based "12 Ways" cosmetics products into additional Watsons Personal Stores in strategic markets in Mainland China.

Related Quotes
Symbol Price Change
KUN 0.60 -0.08


{"s" : "kun","k" : "c10,l10,p20,t10","o" : "","j" : ""} The Company has already launched its "12 Ways" brand of cosmetics products to eleven stores of the Watsons Your Personal Store ("Watsons Stores") in seven cities in China. Watsons Stores is the largest health and beauty retailer in China and Asia. By the end of December, the Company expects to enter an additional eleven Watsons stores in eight different cities including Shenzhen and Guangzhou. Furthermore, the Company is planning to add an additional eleven stores by early 2009 to include cities such as Shanghai and Kunming.

"Watsons Stores is an excellent entry point for China Shenghuo to introduce our high-end '12 Ways' cosmetics products," Mr. Gui Hua Lan, Chief Executive Officer of China Shenghuo, said. "We believe our partnership with Watsons and our anticipated success will give us a greater marketing platform to continue our expansion into other markets."

"12 Ways" cosmetics contain natural ingredients including herbal anti- irritants and anti-oxidants as well as Sanchi, which is the key ingredient for the Company's pharmaceutical products. Introduced in September of 2007, "12 Ways" is the Company's Sanchi-based cosmetics product lines that feature products varying from eye, face and skin creams to shampoos. The Company has already launched a total of 37 different cosmetics products for sale. The "12 Ways" products that are being rolled out to Watsons include Panax Notoginseng Moisture Series, Danshen Spots Fade Series, Yunnan Bamboo Anti-Acne Series, Snow Poria Whitening Series, Sunscreen Series and Eye Care Series.

About Watsons Your Personal Store

Watsons Your Personal Store ("Watsons Stores") is one of the largest health and beauty retail chains in Asia. Currently, Watsons Stores operates in thirteen different markets include Hong Kong, Mainland China, Taiwan, Singapore, Malaysia, Thailand, Indonesia, Macau, Korea, the Philippines, Turkey, Estonia and Slovenia and offers more than 25,000 products in over 1,600 outlets. For additional detail regarding Watsons and its corporate parent A.S. Watson Group, please see http://www.aswatson.com .

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi- based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to, risks of litigation and governmental or other regulatory inquiry or proceedings arising out of or related to any of the matters described in recent press releases, including arising out of the restatement of the Company's financial statements; the Company's continuing ability to satisfy any requirements which may be prescribed by the Exchange for continued listing on the Exchange; potential adverse effects to the Company's financial condition, results of operations or prospects as a result of possible changes to or restatements of prior period financial statements; risks arising from potential weaknesses or deficiencies in the Company's internal control over financial reporting; the Company's reliance on one supplier for Sanchi; the possible effect of adverse publicity on the Company's business, including possible contract cancellation; the Company's ability to develop and market new products; the Company's ability to establish and maintain a strong brand; the Company's continued ability to obtain and maintain all certificates, permits and licenses required to open and operate retail specialty counters to offer its cosmetic products and conduct business in China; protection of the Company's intellectual property rights; market acceptance of the Company's products; changes in the laws of the People's Republic of China that affect the Company's operations; cost to the Company of complying with current and future governmental regulations; the impact of any changes in governmental regulations on the Company's operations; general economic conditions; and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


For more information, please contact:

China Shenghuo Pharmaceutical Holdings, Inc.
Mr. Changhua Mu
Securities Affairs Representative
Tel: [phone]
Email: [e-mail]

Grayling Global
Eddie Cheung
Investor Relations
Tel: [phone]
Email: [e-mail]

[RagingStocks]

"The company has also begun a Phase III clinical trial for Wei Dingkang Soft Capsules, a TCM that treats peptic ulcer disease by inhibiting the growth of helicobacter pylori."

[RagingStocks]

Share Statistics
Average Volume (3 month)3: 7,913.85
Average Volume (10 day)3: 57,155.6
Shares Outstanding5: 19.68M
Float: 4.47M
% Held by Insiders1: N/A
% Held by Institutions1: N/A
Shares Short (as of 24-Nov-08)3: 60.50K
Short Ratio (as of 24-Nov-08)3: 0
Short % of Float (as of 24-Nov-08)3: N/A
Shares Short (prior month)3: 60.50K

[surf1944]

China Shenghuo Announces Delay in Filing Form 10-Q for the Fiscal 2008 Second Quarter and Non-Reliance on Previously Issued Financial Statements
Wednesday August 20, 8:30 am ET

KUNMING, China, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN - News; "China Shenghuo" or the "Company"), announced today that the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2008 (the "Second Quarter 10-Q") would be delayed beyond the filing deadline. The Company had previously filed with the Securities and Exchange Commission, on August 13, 2008, a Form 12b-25 Notification of Late Filing, stating that the Company's Second Quarter 10-Q would not be filed by its due date, August 14, 2008.

This delay is due to a pending internal investigation being conducted by the Audit Committee of the Board of Directors (the "Audit Committee"), based on preliminary information received from Hansen Barnett & Maxwell, P.C., the independent registered public accounting firm of the Company, regarding errors in the accounting for certain sales representative commission advances and trade receivables, the Company's internal controls, the Company's personnel involved and related matters. The Audit Committee intends to engage independent counsel to assist in the investigation. The Company currently anticipates completing the investigation and addressing any accounting or other corrective action deemed appropriate, including adjustments to its fiscal periods ended June 30, September 30, and December 30, 2007 and fiscal quarter ended March 31, 2008 results of operations, within the next two months. The Company currently anticipates that, pending conclusion of the investigation, the Company will restate its financial statements for its fiscal periods ended June 30, September 30, and December 30, 2007 and fiscal quarter ended March 31, 2008, and such financial statements, and the auditors report on such financial statements, should not be relied upon at this time.

As a result of the Company's failure to timely file its Second Quarter 10- Q, the Company may face potential delisting proceedings by the American Stock Exchange ("AMEX"). Pursuant to the AMEX Company Guide Rule 1009(b), the Company anticipates that it will receive a Deficiency Letter from AMEX as a result of its failure to timely file its Second Quarter 10-Q. The Company can provide no assurances that it will regain compliance with AMEX's continued listing requirements and its failure to do so could result in the delisting of the Company's common stock from AMEX.

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi- based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .